The company has received approval from the US Food and Drug Administration (USFDA) to market its product which is a generic equivalent of Wyeth Pharma Inc’s Pristiq tablets
Alembic Pharmaceuticals said recently it has received approval from the US health regulator to market Desenlafaxine extended-release tablets, used to treat major depressive disorder.
The company has received approval from the USFDA to market its product which is a generic equivalent of Wyeth Pharma Inc’s Pristiq tablets, Alembic Pharmaceuticals said in a regulatory filing.
According to IQVIA, Desvenlafaxine extended-release tablets has a market size of around USD 13.3 million for twelve months ending December 2017.